Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Director | February 13, 2020 | February 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date February 13, 2020 · Filed February 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.71 · Expires 2030-02-13 | Direct | 8,888 |
Reported balance
After 2020-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-13 · Grant · Acquired 8,888 · Balance 8,888 F1: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2020 Filed Feb 18, 2020 07:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009864 · doc4.xml · derivative · entry 1 ZOLTNERS ANDRIS A · CIK 0001780665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2030-02-13 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 18:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0001209191-20-005416 · doc4.xml · derivative · entry 3 ZOLTNERS ANDRIS A · CIK 0001780665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2020-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares are fully vested and exercisable. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 18:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 345,000 | $26.50 | $9,142,500.00 |
DisclosureSEC source: 0001209191-20-005416 · doc4.xml · nonDerivative · entry 2 ZOLTNERS ANDRIS A · CIK 0001780665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,621,016 Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 18:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 100,000 | $0.16 | $16,000.00 |
DisclosureSEC source: 0001209191-20-005416 · doc4.xml · nonDerivative · entry 1 ZOLTNERS ANDRIS A · CIK 0001780665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,966,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionSeries F Preferred Stock · Derivative | 223,082 | $0.00 | $0.00 |
DisclosureSEC source: 0001572426-19-000090 · primary_doc.xml · derivative · entry 10 ZOLTNERS ANDRIS A · CIK 0001780665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 223,082 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Reflects automatic conversion of Series F Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. F5 · derivative.exercise_date: Reflects automatic conversion of Series F Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. F5 · derivative.expiration_date: Reflects automatic conversion of Series F Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionSeries E-1 Preferred Stock · Derivative | 454,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001572426-19-000090 · primary_doc.xml · derivative · entry 9 ZOLTNERS ANDRIS A · CIK 0001780665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 454,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Reflects automatic conversion of Series E-1 Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. F4 · derivative.exercise_date: Reflects automatic conversion of Series E-1 Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. F4 · derivative.expiration_date: Reflects automatic conversion of Series E-1 Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionSeries C Preferred Stock · Derivative | 1,895,806 | $0.00 | $0.00 |
DisclosureSEC source: 0001572426-19-000090 · primary_doc.xml · derivative · entry 8 ZOLTNERS ANDRIS A · CIK 0001780665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,895,806 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Reflects automatic conversion of Series C Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. F3 · derivative.exercise_date: Reflects automatic conversion of Series C Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. F3 · derivative.expiration_date: Reflects automatic conversion of Series C Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionSeries B Preferred Stock · Derivative | 992,583 | $0.00 | $0.00 |
DisclosureSEC source: 0001572426-19-000090 · primary_doc.xml · derivative · entry 7 ZOLTNERS ANDRIS A · CIK 0001780665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 992,583 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Reflects automatic conversion of Series B Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. F2 · derivative.exercise_date: Reflects automatic conversion of Series B Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. F2 · derivative.expiration_date: Reflects automatic conversion of Series B Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionSeries A Preferred Stock · Derivative | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001572426-19-000090 · primary_doc.xml · derivative · entry 6 ZOLTNERS ANDRIS A · CIK 0001780665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reflects automatic conversion of Series A Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. F1 · derivative.exercise_date: Reflects automatic conversion of Series A Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. F1 · derivative.expiration_date: Reflects automatic conversion of Series A Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionCommon Stock | 223,082 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001572426-19-000090 · primary_doc.xml · nonDerivative · entry 5 ZOLTNERS ANDRIS A · CIK 0001780665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,866,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Reflects automatic conversion of Series F Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. F5 · price: Reflects automatic conversion of Series F Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionCommon Stock | 454,545 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001572426-19-000090 · primary_doc.xml · nonDerivative · entry 4 ZOLTNERS ANDRIS A · CIK 0001780665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,642,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Reflects automatic conversion of Series E-1 Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. F4 · price: Reflects automatic conversion of Series E-1 Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionCommon Stock | 1,895,806 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001572426-19-000090 · primary_doc.xml · nonDerivative · entry 3 ZOLTNERS ANDRIS A · CIK 0001780665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,188,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Reflects automatic conversion of Series C Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. F3 · price: Reflects automatic conversion of Series C Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionCommon Stock | 992,583 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001572426-19-000090 · primary_doc.xml · nonDerivative · entry 2 ZOLTNERS ANDRIS A · CIK 0001780665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,292,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Reflects automatic conversion of Series B Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. F2 · price: Reflects automatic conversion of Series B Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionCommon Stock | 300,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001572426-19-000090 · primary_doc.xml · nonDerivative · entry 1 ZOLTNERS ANDRIS A · CIK 0001780665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reflects automatic conversion of Series A Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. F1 · price: Reflects automatic conversion of Series A Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.